Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information Part 3: Design considerations

被引:2
|
作者
Ball, Greg [1 ]
Silverman, Michael H. [2 ]
机构
[1] Astellas Pharrna Global Dev, Deerfield, IL 60015 USA
[2] BioStrateg Consulting Ltd, Marblehead, MA 01945 USA
关键词
Safety monitoring; Clinical trials; Blinded treatment; REPEATED SIGNIFICANCE TESTS; SEQUENTIAL MEDICAL TRIALS; INTERIM ANALYSES; PHARMACEUTICAL-INDUSTRY; DRUG DEVELOPMENT; STATISTICS;
D O I
10.1016/j.cct.2011.05.011
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Ongoing safety monitoring of clinical trials of investigational treatments must operate at levels that range from the minute and detailed - namely, mathematical treatment of trial data - to the philosophical and societal - namely, ethical concerns for individuals and populations. Between those two poles lies a realm of environmental and pragmatic considerations that reflect the goals, biases, risk-tolerance, and constraints of study sponsors and organizers. These factors, while more difficult to quantify or, at times, to justify, also have a meaningful impact on the approach to safety monitoring and the resulting actions and outcomes. This paper considers the influence and interaction of two such factors, study design and statistical framework, on continuous safety monitoring procedures. Group sequential designs have been generally preferred for clinical trials over continuous sequential designs because of practical considerations. The group means and greater time for deliberation when using a group sequential procedure, as opposed to a continuous sequential procedure, can improve the quality of the analyses with minimal loss in sensitivity. However, undertaking any sequential analysis within a frequentist framework provokes considerable theoretical and practical difficulties. Continuous monitoring with a likelihood based method, on the other hand, has the advantages that all available information, including new data, can be used: sample sizes need not be fixed: and decisions can be made at any time without statistical penalty, irrespective of trial design. Such responsive statistical rules are needed to provide guidance to the human beings charged with trial monitoring. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:S8 / S10
页数:3
相关论文
共 50 条
  • [1] Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information Part 2: Statistical considerations
    Ball, Greg
    Piller, Linda B.
    CONTEMPORARY CLINICAL TRIALS, 2011, 32 : S5 - S7
  • [2] Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information Part 1: Ethical considerations
    Ball, Greg
    Piller, Linda B.
    Silverman, Michael H.
    CONTEMPORARY CLINICAL TRIALS, 2011, 32 : S2 - S4
  • [3] Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information Part 4: One method
    Ball, Greg
    CONTEMPORARY CLINICAL TRIALS, 2011, 32 : S11 - S17
  • [4] Continuous safety monitoring for randomized controlled clinical trials
    Piller, Linda B.
    Silverman, Michael H.
    Ball, Greg
    CONTEMPORARY CLINICAL TRIALS, 2011, 32 : S1 - S1
  • [5] Blinded continuous monitoring of nuisance parameters in clinical trials
    Friede, Tim
    Miller, Frank
    JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS, 2012, 61 : 601 - 618
  • [6] Blinded continuous information monitoring of recurrent event endpoints with time trends in clinical trials
    Muetze, Tobias
    Salem, Susanna
    Benda, Norbert
    Schmidli, Heinz
    Friede, Tim
    STATISTICS IN MEDICINE, 2020, 39 (27) : 3968 - 3985
  • [7] Blinded continuous monitoring in clinical trials with recurrent event endpoints
    Friede, Tim
    Haring, Dieter A.
    Schmidli, Heinz
    PHARMACEUTICAL STATISTICS, 2019, 18 (01) : 54 - 64
  • [8] Pharmacogenetics in randomized controlled trials: considerations for trial design
    van der Baan, Frederieke H.
    Klungel, Olaf H.
    Egberts, Antoine C. G.
    Leufkens, Hubert G.
    Grobbee, Diederick E.
    Roes, Kit C. B.
    Knol, Mirjam J.
    PHARMACOGENOMICS, 2011, 12 (10) : 1485 - 1492
  • [9] Two-stage Bayesian hierarchical modeling for blinded and unblinded safety monitoring in randomized clinical trials
    Liu, Junhao
    Wick, Jo
    Martin, Renee H.
    Meinzer, Caitlyn
    Roy, Dooti
    Gajewski, Byron
    BMC MEDICAL RESEARCH METHODOLOGY, 2020, 20 (01)
  • [10] Two-stage Bayesian hierarchical modeling for blinded and unblinded safety monitoring in randomized clinical trials
    Junhao Liu
    Jo Wick
    Renee’ H. Martin
    Caitlyn Meinzer
    Dooti Roy
    Byron Gajewski
    BMC Medical Research Methodology, 20